Abstracts tagged "giant cell arteritis"

Abstract Number: 1623 • ACR Convergence 2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez-Álvaro², Javier Narvaez-García³, Noemí Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez-Martín¹¹, Itziar Calvo¹², Vicente Aldasoro¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, Patricia Moya¹⁶, María García-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, San Sebastián, Spain, ¹⁰Hospital León, LEON, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹University of Cantabria. IDIVAL, Santander, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a predominantly female vasculitis. There are several studies that attempt to report the differences in the presentation of this…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 0743 • ACR Convergence 2024
Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study
Elvis Hysa¹, Dario Camellino², Cristina Bernini³, Paolo Vittoriano Clini⁴, Matteo Bauckneht⁵, silvia Morbelli⁶, Gianmario Sambuceti⁵, Emanuele Gotelli⁷, Alberto Sulli⁸, Maurizio Cutolo⁷ and Marco Amedeo Cimmino¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Division of Rheumatology, Local Health Trust 3, Genoa, Italy, ³Emergency Medicine Department, San Martino Polyclinic Hospital, Genoa, Italy,, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Nuclear Medicine Unit and Department of Health Sciences, University of Genova, Genoa, Italy, Genoa, Italy, ⁶University of Torino, Torino, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases characterized by increased musculoskeletal and vascular uptakes of 18-Fluorodeoxyglucose (18F-FDG) at positron…
Abstract Number: 0770 • ACR Convergence 2024
Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial
Peter Merkel¹, Sara Penn², Arathi Setty², Wolfgang Schmidt³, Andrea Rubbert-Roth⁴, Ellen Margrethe Hauge⁵, Helen Keen⁶, Tomonori Ishii⁷, Nader Khalidi⁸, Liu Meng², weihan zhao², Ivan Lagunes⁹, Ana B. Romero², Peter Wung¹⁰ and daniel blockmans¹¹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Aarhus Universitetshospital, Aarhus, Denmark, ⁶University of Western Australia, Daglish, Western Australia, Australia, ⁷Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁸McMaster University, Hamilton, ON, Canada, ⁹Abbvie, Inc, North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: The objective was to assess the efficacy and safety of UPA vs placebo (PBO), in combination with a GC taper regimen, in patients with…
Abstract Number: 1624 • ACR Convergence 2024
Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
Julio Sánchez-Martín¹, Javier Loricera², Isabel Martinez-Rodriguez³, ivan Ferraz-Amaro⁴, Nestor Martinez-Amador⁵, Remedios Quirce-Pisano⁵, Fernando Lopez-Gutierrez⁶ and Ricardo Blanco-Alonso⁷, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁵Department of Nuclear Medicine, Hospital Universitario Marqués de Valdecilla, Molecular Imaging Group, IDIVAL, Santander., Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan has become a very useful diagnostic tool in patients with GCA with large vessel involvement. However,…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 0744 • ACR Convergence 2024
Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry
Adrián Martín-Gutiérrez¹, Juan Molina-Collada², Marta Domínguez-Álvaro³, Rafael Benito Melero-Gonzalez⁴, Elisa Fernández-Fernández:⁵, Maite Silva-Diaz⁶, Jesús Alejandro Valero⁷, Ismael Gonzalez⁸, Julio Sánchez-Martín⁹, Javier Narvaez-García¹⁰, Itziar Calvo¹¹, Vicente Aldasoro¹², lydia Abasolo Alcazar¹³, ALBERTO MARIANO RUIZ ROMAN¹⁴, Javier Loricera¹⁵, Santos Castañeda¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴CHU Ourense, O Carballino, Spain, ⁵La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁶Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁷Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁸Complejo Asistencial Universitario de Leon, León, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital Universitario de Basurto, Bilbao, Spain, ¹²Hospital Universitario de Navarra, Pamplona, Spain, ¹³IdISSC. HCSC, Madrid, Spain, ¹⁴Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
Abstract Number: 0854 • ACR Convergence 2024
The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Valentin Sebastian Schäfer¹, Tobias Schremmer², Florian Recker³, Wolfgang Hartung⁴, Christina Duftner⁵, Sara Monti⁶, Alojzija Hocevar⁷, Rositsa Karalilova⁸, Annamaria Iagnocco⁹, pierluigi macchioni¹⁰, Giuseppe Antonio Germano¹¹, ESPERANZA NAREDO¹², Eugenio De Miguel¹³, Luca Seitz¹⁴, Thomas Daikeler¹⁵, Dennis Boumans¹⁶, Chetan Mukhtyar¹⁷, Kate Smith¹⁸, Richard Wakefield¹⁸, Andreas Diamantopoulos¹⁹, Stavros Chrysidis²⁰, Berit Dalsgaard Nielsen²¹, Kresten Keller²², Uffe Moller Dohn²³, Lene Terslev²⁴, Marcin Milchert²⁵, Wolfgang Schmidt²⁶, George A. W. Bruyn²⁷, Aaron Juche²⁸ and Christian Dejaco²⁹, ¹Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, 53127 Bonn, Nordrhein-Westfalen, Germany, ²Helios Klinikum Bonn/Rhein-Sieg, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Germany, Bonn, Germany, ⁴Asklepios Clinic, Tegernheim, Germany, ⁵Medical University Innsbruck/Tirol Kliniken GmbH, Innsbruck, Austria, ⁶IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁷University Medical Center Ljubljana, LJUBLJANA, Slovenia, ⁸Medical University of Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁹University of Turin, Italy, Roma, Italy, ¹⁰SERVIZIO REUMATOLOGIA IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ¹¹Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, ¹²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Inselspital, Liebefeld, Switzerland, ¹⁵university hospital, Basel, Switzerland, ¹⁶Ziekenhuisgroep Twente (Hospital Group Twente), Borne, Netherlands, ¹⁷Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁸NIHR Leeds Biomedical Research Centre, Leeds, UK., Leeds, United Kingdom, ¹⁹Akershus University Hospital, Lørenskog, Norway, ²⁰Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ²¹Department of Rheumatology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, Vejle, Denmark, ²²Aarhus University Hospital, Aarhus, Denmark, ²³Rigshospitalet-Glostrup, Glostrup, Denmark, ²⁴Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ²⁵Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology, Pomeranian Medical University, Szczecin, Poland., Szczecin, Poland, ²⁶Immanuel Krankenhaus Berlin, Berlin, Germany, ²⁷Reumakliniek Lelystad, Loenga, Netherlands, ²⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, Berlin, Germany, ²⁹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). Due to the urgent need for glucocorticoid treatment in acute GCA…
Abstract Number: 1625 • ACR Convergence 2024
Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
Alae Dhahbi¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Sélène Meunier², Hussein Baalbaki², Carolyn Ross⁴ and Jean-Paul Makhzoum⁴, ¹Laval University, Quebec, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Sherbrooke, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background/Purpose: Giant cell arteritis (GCA) is both a medical emergency and diagnostic challenge. Up to 45% of patients may require emergency department (ED) visits and/or…
Abstract Number: 2000 • ACR Convergence 2024
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Jeanne Tisseau des Escotais¹, Camille Taille², Julie Merindol³, Matthieu Groh⁴, Perrine SMETS⁵, Amel Boudjemaa⁶, Alexandra Audemard⁷, Nabil Belfeki⁸, Philippe Bonniaud⁹, Chloe Comarmond¹⁰, Isabelle DELACROIX¹¹, Charlotte Descours¹², Lucile Grange¹³, Paul Legendre¹⁴, Nihal Martis¹⁵, Thomas Moulinet¹⁶, Béatrice Walls¹⁷, Laurent Chouchana¹ and Benjamin Terrier¹⁸, ¹Cochin, Paris, France, ²Bichat Hospital, Paris, France, ³Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ⁴Foch, Suresnes, France, ⁵Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁶CHU créteil, Créteil, France, ⁷Tours, Tours, France, ⁸CH Melun, Melun, France, ⁹Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ¹⁰Lariboisière University Hospital, Paris, France, ¹¹CHI créteil, Créteil, France, ¹²CH Tours, Tours, France, ¹³CH Saint-Etienne, Saint-Etienne, France, ¹⁴Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ¹⁵CH Nice, Nice, France, ¹⁶CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁷Paris, Paris, France, ¹⁸Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
Abstract Number: 0745 • ACR Convergence 2024
Tocilizumab in Monotherapy vs. Combined in Aortitis Associated with Giant Cell Arteritis. Multicenter Open-label Study of 196 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Javier Narvaez-García⁴, Olga Maíz Alonso⁵, Iñigo Hernández-Rodríguez⁶, Susana Romero Yuste⁷, Eugenio De Miguel⁸, Eva Galindez-Agirregoikoa⁹, ivan Ferraz-Amaro¹⁰, Julio Sánchez-Martín¹¹, Patricia Moya Albarado¹², Cristina Campos Fernández¹³, Fernando Lopez-Gutierrez¹⁴, Santos Castañeda¹⁵ and Ricardo Blanco-Alonso¹⁶, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁶Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁷Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital de San Pau, Barcelona, Spain, ¹³Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹⁵Hospital Universitario de la Princesa, Madrid, Spain, ¹⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis related to Giant Cell Arteritis (GCA-aortitis) is a frequent and potential severe complication. Tocilizumab (TCZ) was approved in GCA, but the efficacy in…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
Abstract Number: 1626 • ACR Convergence 2024
Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
Sagar Patel¹, Iva Okaj², Jessica Scott³, Sukhreet Atwal³, Colin Stark³, Rabia Tahir³, Nader Khalidi² and Mats Junek², ¹McMaster University, Brampton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McMaster University, Hamilton, Canada
Background/Purpose: Giant cell arteritis is being increasingly recognized to occur in intracranial vessels. The clinical significance of intracranial GCA (ICGCA) is unknown; previous cases have…
Abstract Number: 2150 • ACR Convergence 2024
Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Pallavi Arun¹, Nikita Parashar¹, Sakshi Sharma¹, Kanika Arora¹, Vandana Padmanabhan¹ and Alvaro Arjona², ¹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ²Novartis Farmaceutica, S.A., Madrid, Madrid, Spain
Background/Purpose: Analyzing social media conversations of patients (pts) and caregivers can be useful to understand the real-world perspectives thereby improving quality of healthcare.1 GCA and…
Abstract Number: 0751 • ACR Convergence 2024
Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Javier Narvaez-García¹, Marta Domínguez-Álvaro², Eva Galíndez-Agirregoikoa³, Javier Mendizabal⁴, lydia Abasolo Alcazar⁵, Javier Loricera⁶, Noemí Garrido-Puñal⁷, Santos Castañeda⁸, Patricia Moya⁹, Carmen Larena¹⁰, Paula Estrada-Alarcón¹¹, Carlos Galisteo¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuan¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota Laura Iniguez Ubiaga¹⁷, Maria Garcia-Gonzalez¹⁸ and Ricardo Blanco-Alonso¹⁹, and ARTESER Project Collaborative Group, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Basurto, Bilbao, Spain, ⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ⁵IdISSC. HCSC, Madrid, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹²Hospital Universitario Parc Taulí, Sabadell, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷SERV. REUMATOLOGIA, Lugo, Spain, ¹⁸Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ¹⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: To evaluate the frequency and timing of sustained drug-free remission (SDFR) in a Spanish cohort of patients with giant cell arteritis (GCA) and to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.